Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.

Abstract: A percutaneous bypass method for implanting a bypass graft between two vessels is described. The bypass graft comprises a first part and a second part, each having a tubular shape and comprising respective lumens. The method comprises the step of inserting a second sheath, from the outside to the inside of a bypass portion of the first part, through a puncture therein, and retracting the second sheath so as to deploy and implant a hook portion of the second part into the second vessel, and deploy a bypass portion of the second part outside the second vessel, from the second vessel to the first part, and within the lumen of the first part.

Abstract: A memory cell, includes first and second main terminals, an auxiliary terminal; M memristor(s) between the main terminals, M?1; M primary switch(es), each in parallel with a memristor; and a secondary switch between the second main terminal and the auxiliary terminal. It is configured for writing to at least one memristor by opening each primary switch in parallel with the at least one memristor, closing each other primary switch, closing the secondary switch and applying a corresponding programming voltage between the first main terminal and the auxiliary terminal; and for reading at least one memristor by opening each primary switch in parallel with the at least one memristor, closing each other possible primary switch, opening the secondary switch and measuring a corresponding electrical quantity between the main terminals.

Abstract: The use of UV-activated Copper Radical Oxidase (CRO) enzymes in the implementation of oxidation reactions. Also, a process for oxidizing organic compounds using enzymes which are activated by UV light. The process also leads to concomitant formation of hydrogen peroxide, that can optionally be used in hydrogen peroxide mediated processes. Further, the process relates to the oxidation of alcohols in aldehydes.

Abstract: A system is described for emitting a radiofrequency field for a magnetic resonance imaging device, including a volumetric antenna that emits a radiofrequency field, a device for homogenizing the radiofrequency field arranged between said volume antenna and a part of the body to be imaged. The device may include a first continuous metal track with an overall length of approximately 0.5 to approximately 1.5 times said wavelength of the radio frequency field. The first metallic track may occupy a surface with a largest dimension ranging between approximately 5% and approximately 15% of said wavelength of the radio frequency field. The first metal track is arranged in a pattern including a plane of symmetry that is normal to the electrical component of the radio frequency field, so as to give the device an electric dipole property including a natural frequency strictly greater than the frequency of the radio frequency field.

Abstract: The invention relates to a method for coupling in-line the analysis of molecular interactions by surface plasmon resonance (SPR) with a structural identification by mass spectrometry using the same functionalized support for both types of analysis.

Abstract: The present invention relates to an in vitro method for determine the prognosis of the survival time of a patient suffering from a cancer comprising the steps consisting of i) determining the expression level of the couple DNMT3A/ISGF3? in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis when the expression level is lower than the predetermined reference value and a poor prognosis when the expression level is higher than the predetermined reference value. The invention also relates a compound which is a DNMT3A/ISGF3? antagonist or a compound which is a DNMT3A/ISGF3? gene expression inhibitor for use in the treatment and prevention of cancer.

Abstract: The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.

Abstract: The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.

Abstract: The method for inferring epileptogenicity of a brain region not observed as recruited or not observed as not recruited, in a seizure activity of an epileptic patient brain, includes: providing a computerized model modelling various regions of a primate brain and connectivity between the regions; providing the computerized model with a model able to reproduce an epileptic seizure dynamic in the primate brain; providing structural data of the epileptic patient brain and personalizing the computerized model using the structural data to obtain a virtual epileptic patient (VEP) brain model; translating a state-space representation of the VEP brain model into a probabilistic programming language (PPL) using probabilistic state transitions to obtain a probabilistic virtual epileptic patient brain model (BVEP); and acquiring electro- or magneto-encephalographic data of the patient brain and fitting the probabilistic VEP brain model against the data to infer the epileptogenicity of the brain region that is not observe

Abstract: A mixing tube with multiple shapes is provided, allowing additional injection of gas in order to keep the flow detached from the second shape in an ascent phase and to bring about, in a descent phase, a controlled detachment as a result of the change of slope between the two shapes. A propulsion nozzle for an engine of a spacecraft or aircraft is provided including such a mixing tube and a method for controlling the speed transition of the propulsion gases in such a nozzle in accordance with the altitude. Also, a method is provided for vectorising the thrust in such a nozzle by radial and asymmetrical injection of gas and a control method which prevents re-attachment of the jet to the second shape of such a propulsion nozzle for an engine of a spacecraft when it is in the take-off or landing phase.

Abstract: The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the ?I7I-I85cit peptide of amino acid sequence VDIDIKIX1SCX2GSCS (SEQ ID NO: 8) wherein X1 and X2 each represent a citmllyl residue, —the ?62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X1 and X2 each represent a citmllyl residue.

Abstract: Disclosed is a functionalizing method for the end functionalisation of trans-1,4 stereo-regular polydiene chains obtained by the coordination catalytic polymerisation of at least one conjugated diene monomer. It also relates to a polydiene having a trans-1,4 chain formation rate of at least 85%, preferably at least 90%, and an end functionalisation rate higher than 70%, preferably higher than 80%, and more preferably higher than 90%.

Abstract: A communication entity for transmitting a video data stream at a target transmission bit rate and corresponding method are provided. The communication entity comprises: a first scheduling instance configured to determine a preliminary transmission bit rate for forwarding the video data stream towards the user equipment; and a second scheduling instance configured to determine the target transmission bit rate based on the preliminary transmission bit rate and a set of video bit rates, the set of video bit rates comprising a first video bit rate associated with a first video quality and a second video bit rate associated with a second video quality, the first video bit rate being smaller than the second video bit rate, wherein the second scheduling instance is configured to select the preliminary transmission bit rate as the target transmission bit rate if the preliminary transmission bit rate does not exceed the first video bit rate.

Abstract: The present invention relates to regulatory T cell and uses thereof. By their immunosuppressive and anti-inflammatory activities, regulatory T cells play a central role in peripheral tolerance and thus critically prevent the development of autoimmune and inflammatory disorders. The inventors showed that Foxp3+CD4+ Tregs express high levels of LT?, which negatively regulates their immunosuppressive signature. They demonstrated that the adoptive transfer of LT??/? Tregs in mice protects from dextran sodium sulfate (DSS)-induced colitis and attenuates inflammatory bowel disease (IBD), multi-organ autoimmunity and the development of CAC. The inventors also showed that by mixed bone marrow chimeras that LT? expression specifically in hematopoietic cells negatively controls the immunosuppressive signature of Tregs. In particular, the present invention relates to regulatory T cell characterized in that it does not express or expresses reduced levels of lymphotoxin alpha.

Abstract: The present invention concerns a compound having the following formula (I): as well as its use as a medicament, especially for its use for treating viral infections.

Abstract: Disclosed is a non-invasive method for assessing in a subject the presence and severity of a liver lesion, or the risk of death or liver-related events, including: 1) performing at least three binary logistic regressions on at least one variable, performed on the same variable(s) but each directed to a different single diagnostic target, thereby obtaining at least three scores; 2) combining the scores from step 1) in a multiple linear regression to obtain a new multi-targeted score; 3) optionally sorting the multi-targeted score obtained in step 2) in a classification of liver lesion stages or grades, thereby determining to which liver lesion stage or grade the subject belongs based on his/her multi-targeted score. Also disclosed is a single multi-targeted non-invasive test obtained by the combination of single-targeted non-invasive tests providing a unique score and a unique classification with improved accuracy compared to single-targeted diagnostic tests.

Abstract: The present invention concerns synthetic polynucleotides encoding a human fukutin-related protein (FKRP) wherein the synthetic polynucleotides contain at least a mutation avoiding supplementary transcript(s) generated from frameshift start codon(s). The synthetic polynucleotides are useful, especially for treating a pathology linked to a FKRP deficiency or induced by a defect in ?-dystroglycan (?-DG) glycosylation, such as LGMD2I.

Abstract: The present invention relates to a neuromorphic circuit suitable for implementing a neural network, the neuromorphic circuit comprising: lines of words, pairs of complementary bit-lines, source lines, a set of elementary cells, an electronic circuit implementing a neurone having an output and including: a set of logic components, a counting unit, a comparison unit comprising a comparator and a comparison voltage generator, the comparator being suitable for comparing the output of the counting unit with the comparison voltage generated by the comparison voltage generator in order to output a signal dependent on the comparison and corresponding to the output of the electronic circuit which implements a neurone.

Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.